PTEN and myotubularin: novel phosphoinositide phosphatases
- PMID: 11395408
- DOI: 10.1146/annurev.biochem.70.1.247
PTEN and myotubularin: novel phosphoinositide phosphatases
Abstract
Protein tyrosine phosphatases (PTPs) are a diverse group of enzymes that contain a highly conserved active site motif, Cys-x5-Arg (Cx5R). The PTP superfamily enzymes, which include tyrosine-specific, dual specificity, low-molecular-weight, and Cdc25 phosphatases, are key mediators of a wide variety of cellular processes, including growth, metabolism, differentiation, motility, and programmed cell death. The PTEN/MMAC1/TEP1 gene was originally identified as a candidate tumor suppressor gene located on human chromosome 10q23; it encodes a protein with sequence similarity to PTPs and tensin. Recent studies have demonstrated that PTEN plays an essential role in regulating signaling pathways involved in cell growth and apoptosis, and mutations in the PTEN gene are now known to cause tumorigenesis in a number of human tissues. In addition, germ line mutations in the PTEN gene also play a major role in the development of Cowden and Bannayan-Zonana syndromes, in which patients often suffer from increased risk of breast and thyroid cancers. Biochemical studies of the PTEN phosphatase have revealed a molecular mechanism by which tumorigenesis may be caused in individuals with PTEN mutations. Unlike most members of the PTP superfamily, PTEN utilizes the phosphoinositide second messenger, phosphatidylinositol 3,4,5-trisphosphate (PIP3), as its physiologic substrate. This inositol lipid is an important regulator of cell growth and survival signaling through the Ser/Thr protein kinases PDK1 and Akt. By specifically dephosphorylating the D3 position of PIP3, the PTEN tumor suppressor functions as a negative regulator of signaling processes downstream of this lipid second messenger. Mutations that impair PTEN function result in a marked increase in cellular levels of PIP3 and constitutive activation of Akt survival signaling pathways, leading to inhibition of apoptosis, hyperplasia, and tumor formation. Certain structural features of PTEN contribute to its specificity for PIP3, as well as its role(s) in regulating cellular proliferation and apoptosis. Recently, myotubularin, a second PTP superfamily enzyme associated with human disease, has also been shown to utilize a phosphoinositide as its physiologic substrate.
Similar articles
-
PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease.Trends Cell Biol. 2002 Dec;12(12):579-85. doi: 10.1016/s0962-8924(02)02412-1. Trends Cell Biol. 2002. PMID: 12495846 Review.
-
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.Cancer Res. 1999 Nov 15;59(22):5808-14. Cancer Res. 1999. PMID: 10582703
-
PTEN: life as a tumor suppressor.Exp Cell Res. 2001 Mar 10;264(1):29-41. doi: 10.1006/excr.2000.5130. Exp Cell Res. 2001. PMID: 11237521 Review.
-
Pten signaling in gliomas.Neuro Oncol. 2002 Jul;4(3):196-211. Neuro Oncol. 2002. PMID: 12084351 Free PMC article. Review.
-
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.Eur J Biochem. 1999 Aug;263(3):605-11. doi: 10.1046/j.1432-1327.1999.00542.x. Eur J Biochem. 1999. PMID: 10469123 Review.
Cited by
-
Mining oomycete proteomes for phosphatome leads to the identification of specific expanded phosphatases in oomycetes.Mol Plant Pathol. 2024 Mar;25(3):e13425. doi: 10.1111/mpp.13425. Mol Plant Pathol. 2024. PMID: 38462784 Free PMC article.
-
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.Pharmacol Rep. 2024 Apr;76(2):273-286. doi: 10.1007/s43440-024-00568-7. Epub 2024 Feb 22. Pharmacol Rep. 2024. PMID: 38388810 Review.
-
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy.Cancers (Basel). 2023 Nov 21;15(23):5499. doi: 10.3390/cancers15235499. Cancers (Basel). 2023. PMID: 38067203 Free PMC article. Review.
-
Genetic alterations shape innate immune cells to foster immunosuppression and cancer immunotherapy resistance.Clin Exp Med. 2023 Dec;23(8):4289-4296. doi: 10.1007/s10238-023-01240-9. Epub 2023 Nov 1. Clin Exp Med. 2023. PMID: 37910258 Review.
-
Clinical and preclinical evaluation of miR-144-5p as a key target for major depressive disorder.CNS Neurosci Ther. 2023 Nov;29(11):3598-3611. doi: 10.1111/cns.14291. Epub 2023 Jun 12. CNS Neurosci Ther. 2023. PMID: 37308778 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous